UNSPSC 51332810: Cyamemazine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H21N3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A2JGV5CNU4, chemically known as 10h-phenothiazine-2-carbonitrile, 10-(3-(dimethylamino)-2-methylpropyl)- (9ci) but generally known as cyamemazine, which bears US NIH Compound Identifier 62865. European Medicines Agency schedules Cyamemazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06836MIG.

UNSPSC 51332810 Cyamemazine is a Commodity code that designates a specific pharmaceutical product, yet the recent state and local procurement activity tagged under this code does not align with its nominal scope. Seminole County, Florida posted an IFB (IFB60459723LAS) in June 2026 for Naloxone and Safe Drug Deactivation Systems—neither of which are cyamemazine. The mismatch suggests either a tagging error in the county's procurement system or a broad categorization practice that does not reflect actual purchasing intent under this code. State and local governments use UNSPSC codes to organize pharmaceutical and medical supply procurement, but the specificity of a commodity-level code like cyamemazine does not appear to drive routine demand signals across multiple issuing bodies.

The Seminole County opportunity represents the only recent activity visible under this code in the provided dataset. That procurement sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, structured as a two-year term with a one-year renewal option. The IFB closed on July 26, 2023 (a discrepancy with the June 2026 posting date suggests data quality issues in the source). Vendors were required to submit electronic bids through the county e-procurement portal, include all shipping and delivery costs, maintain workers' compensation and commercial general liability insurance, and comply with E-Verify requirements. The contract was potentially FEMA-funded, introducing federal compliance obligations. No explicit set-aside designations were noted. The code shows little relevant recent activity suitable for business development targeting under its stated pharmaceutical scope.